IKZF1 Δ2-8/ALB gene deletions and MRD
There were no statistically significant differences between the two
groups in the level of MRD at the 15th or 33rd day of induction
chemotherapy or in the incidence of CNSL. In Group B, 34.5% of the
patients were refractory/relapsed, which was significantly higher than
Group A (34.5% vs. 13.3%, P =0.031). The mortality in Group B
was significantly higher than Group A (17.2% vs. 2.2%, P =0.02),
as shown in Table 1.